5-HT7 receptor: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Alter: issue. Add: pmc. You can use this bot yourself. Report bugs here.)
imported>Citation bot
m (Alter: volume, issue, pages. Formatted dashes. | You can use this bot yourself. Report bugs here. | User-activated.)
 
Line 16: Line 16:
== Discovery ==
== Discovery ==


In 1983, evidence for a [[5-HT1|5-HT<sub>1</sub>]]-like receptor was first found.<ref>{{cite journal | vauthors = Feniuk W, Humphrey PP, Watts AD | title = 5-Hydroxytryptamine-induced relaxation of isolated mammalian smooth muscle | journal = European Journal of Pharmacology | volume = 96 | issue = 1–2 | pages = 71–8 | date = December 1983 | pmid = 6662198 | doi = 10.1016/0014-2999(83)90530-7 }}</ref> Ten years later, 5-HT<sub>7</sub> receptor was cloned and characterized.<ref name="pmid8226867" /> It has since become clear that the receptor described in 1983 is 5-HT<sub>7</sub>.<ref>{{cite journal | vauthors = Hoyer D, Hannon JP, Martin GR | title = Molecular, pharmacological and functional diversity of 5-HT receptors | journal = Pharmacology, Biochemistry, and Behavior | volume = 71 | issue = 4 | pages = 533–54 | date = April 2002 | pmid = 11888546 | doi = 10.1016/S0091-3057(01)00746-8 }}</ref>
In 1983, evidence for a [[5-HT1|5-HT<sub>1</sub>]]-like receptor was first found.<ref>{{cite journal | vauthors = Feniuk W, Humphrey PP, Watts AD | title = 5-Hydroxytryptamine-induced relaxation of isolated mammalian smooth muscle | journal = European Journal of Pharmacology | volume = 96 | issue = 1–2 | pages = 71–8 | date = December 1983 | pmid = 6662198 | doi = 10.1016/0014-2999(83)90530-7 }}</ref> Ten years later, 5-HT<sub>7</sub> receptor was cloned and characterized.<ref name="pmid8226867" /> It has since become clear that the receptor described in 1983 is 5-HT<sub>7</sub>.<ref>{{cite journal | vauthors = Hoyer D, Hannon JP, Martin GR | title = Molecular, pharmacological and functional diversity of 5-HT receptors | journal = Pharmacology Biochemistry and Behavior | volume = 71 | issue = 4 | pages = 533–54 | date = April 2002 | pmid = 11888546 | doi = 10.1016/S0091-3057(01)00746-8 }}</ref>


== Clinical significance ==
== Clinical significance ==


This receptor gene is a candidate [[gene locus|locus]] for involvement in [[autism|autistic]] disorder and other neuropsychiatric disorders.<ref name="pmid10490701">{{cite journal | vauthors = Lassig JP, Vachirasomtoon K, Hartzell K, Leventhal M, Courchesne E, Courchesne R, Lord C, Leventhal BL, Cook EH | title = Physical mapping of the serotonin 5-HT(7) receptor gene (HTR7) to chromosome 10 and pseudogene (HTR7P) to chromosome 12, and testing of linkage disequilibrium between HTR7 and autistic disorder | journal = American Journal of Medical Genetics | volume = 88 | issue = 5 | pages = 472–5 | date = October 1999 | pmid = 10490701 | doi = 10.1002/(SICI)1096-8628(19991015)88:5<472::AID-AJMG7>3.0.CO;2-G }}</ref>
This receptor gene is a candidate [[gene locus|locus]] for involvement in [[autism]] and other neuropsychiatric conditions.<ref name="pmid10490701">{{cite journal | vauthors = Lassig JP, Vachirasomtoon K, Hartzell K, Leventhal M, Courchesne E, Courchesne R, Lord C, Leventhal BL, Cook EH | title = Physical mapping of the serotonin 5-HT(7) receptor gene (HTR7) to chromosome 10 and pseudogene (HTR7P) to chromosome 12, and testing of linkage disequilibrium between HTR7 and autistic disorder | journal = American Journal of Medical Genetics | volume = 88 | issue = 5 | pages = 472–5 | date = October 1999 | pmid = 10490701 | doi = 10.1002/(SICI)1096-8628(19991015)88:5<472::AID-AJMG7>3.0.CO;2-G }}</ref>


== Ligands ==
== Ligands ==


Numerous ligands [[binding (molecular)|bind]] to the 5-HT<sub>7</sub> receptor with moderate to high affinity.
Numerous orthosteric ligands of moderate to high affinity are known. [[Functional selectivity|Signaling biased ligands]] were discovered and developed in 2018.<ref name="pmid30028132">{{cite journal |vauthors=Kim Y, Kim H, Lee J, Lee JK, Min SJ, Seong J, Rhim H, Tae J, Lee HJ, Choo H |title=Discovery of β-Arrestin Biased Ligands of 5-HT7R |journal=J. Med. Chem. |volume= 61|issue= 16|pages= 7218–7233|date=August 2018 |pmid=30028132 |doi=10.1021/acs.jmedchem.8b00642 |url=}}</ref>


=== Agonists ===
=== Agonists ===


[[Agonists]] mimic the effects of the endogenous ligand, which is serotonin at the 5-HT<sub>7</sub> receptor (↑cAMP).
[[Agonists]] mimic the effects of the endogenous ligand, which is serotonin at the 5-HT<sub>7</sub> receptor (↑cAMP).
{{div col|30em}}
{{Div col|colwidth=30em}}
* [[5-Carboxamidotryptamine]] (5-CT)
* [[5-Carboxamidotryptamine]] (5-CT)
* [[5-methoxytryptamine]] (5-MT, 5-MeOT)
* [[5-methoxytryptamine]] (5-MT, 5-MeOT)
Line 40: Line 40:
* [[LP-44]] (4-[2-(Methylthio)phenyl]-N-(1,2,3,4-tetrahydro-1-naphthalenyl)-1-piperazinehexanamide)
* [[LP-44]] (4-[2-(Methylthio)phenyl]-N-(1,2,3,4-tetrahydro-1-naphthalenyl)-1-piperazinehexanamide)
* [[LP-211]]
* [[LP-211]]
* [[LSD]]
* [[MSD-5a]]<ref name="pmid19118950">{{cite journal | vauthors = Brenchat A, Romero L, García M, Pujol M, Burgueño J, Torrens A, Hamon M, Baeyens JM, Buschmann H, Zamanillo D, Vela JM | title = 5-HT7 receptor activation inhibits mechanical hypersensitivity secondary to capsaicin sensitization in mice | journal = Pain | volume = 141 | issue = 3 | pages = 239–47 | date = February 2009 | pmid = 19118950 | doi = 10.1016/j.pain.2008.11.009 }}</ref>
* [[MSD-5a]]<ref name="pmid19118950">{{cite journal | vauthors = Brenchat A, Romero L, García M, Pujol M, Burgueño J, Torrens A, Hamon M, Baeyens JM, Buschmann H, Zamanillo D, Vela JM | title = 5-HT7 receptor activation inhibits mechanical hypersensitivity secondary to capsaicin sensitization in mice | journal = Pain | volume = 141 | issue = 3 | pages = 239–47 | date = February 2009 | pmid = 19118950 | doi = 10.1016/j.pain.2008.11.009 }}</ref>
* [[N-Methylserotonin|''N<sub>ω</sub>''-Methylserotonin]]<ref name="Powell et al.">{{cite journal | vauthors = Powell SL, Gödecke T, Nikolic D, Chen SN, Ahn S, Dietz B, Farnsworth NR, van Breemen RB, Lankin DC, Pauli GF, Bolton JL | title = In vitro serotonergic activity of black cohosh and identification of N(omega)-methylserotonin as a potential active constituent | journal = Journal of Agricultural and Food Chemistry | volume = 56 | issue = 24 | pages = 11718–26 | date = December 2008 | pmid = 19049296 | pmc = 3684073 | doi = 10.1021/jf803298z }}</ref>
* [[N-Methylserotonin|''N<sub>ω</sub>''-Methylserotonin]]<ref name="Powell et al.">{{cite journal | vauthors = Powell SL, Gödecke T, Nikolic D, Chen SN, Ahn S, Dietz B, Farnsworth NR, van Breemen RB, Lankin DC, Pauli GF, Bolton JL | title = In vitro serotonergic activity of black cohosh and identification of N(omega)-methylserotonin as a potential active constituent | journal = Journal of Agricultural and Food Chemistry | volume = 56 | issue = 24 | pages = 11718–26 | date = December 2008 | pmid = 19049296 | pmc = 3684073 | doi = 10.1021/jf803298z }}</ref>
Line 46: Line 45:
* [[N,N-Dimethyltryptamine]]
* [[N,N-Dimethyltryptamine]]
* [[1-(2-Diphenyl)piperazine|RA-7]] (1-(2-diphenyl)piperazine)
* [[1-(2-Diphenyl)piperazine|RA-7]] (1-(2-diphenyl)piperazine)
{{Div col end}}
* [[AGH-107]] (3‐(1‐ethyl‐1H‐imidazol‐5‐yl)‐5‐iodo‐1H‐indole) <ref name="pmid28473721">{{cite journal | vauthors = Hogendorf AS, Hogendorf A, Kurczab R, Satała G, Lenda T, Walczak M, Latacz G, Handzlik J, Kieć-Kononowicz K, Wierońska JM, Woźniak M, Cieślik P, Bugno R, Staroń J, Bojarski AJ | title = Low-basicity 5-HT7 Receptor Agonists Synthesized Using the van Leusen Multicomponent Protocol | journal = Scientific Reports | volume = 7 | pages = 1444 | number= 1444 | date = May 2017 | pmid = 28473721 | pmc = 5431432 | doi = 10.1038/s41598-017-00822-4 }}</ref>{{Div col end}}


=== Antagonists ===
=== Antagonists ===
Line 52: Line 51:
[[receptor antagonist|Neutral antagonists]] (also known as silent antagonists) bind the receptor and have no [[Efficacy|intrinsic activity]] but will block the activity of agonists or inverse agonists. [[Inverse agonists]] inhibit the [[Receptor (biochemistry)#Constitutive activity|constitutive activity]] of the receptor, producing functional effects opposite to those of agonists (at the 5-HT<sub>7</sub> receptor: ↓cAMP).<ref name="pmid17897083">{{cite journal | vauthors = Pittalà V, Salerno L, Modica M, Siracusa MA, Romeo G | title = 5-HT7 receptor ligands: recent developments and potential therapeutic applications | journal = Mini Reviews in Medicinal Chemistry | volume = 7 | issue = 9 | pages = 945–60 | date = September 2007 | pmid = 17897083 | doi = 10.2174/138955707781662663 }}</ref><ref name="pmid15032609">{{cite journal | vauthors = Leopoldo M | title = Serotonin(7) receptors (5-HT(7)Rs) and their ligands | journal = Current Medicinal Chemistry | volume = 11 | issue = 5 | pages = 629–61 | date = March 2004 | pmid = 15032609 | doi = 10.2174/0929867043455828 }}</ref> Neutral antagonists and inverse agonists are typically referred to collectively as "antagonists" and, in the case of the 5-HT<sub>7</sub> receptor, differentiation between neutral antagonists and inverse agonists is problematic due to differing levels inverse agonist efficacy between receptor splice variants. For instance, mesulergine and metergoline are reported to be neutral antagonists at the h5-HT<sub>7(a)</sub> and h5-HT<sub>7(d)</sub> receptor isoforms but these drugs display marked inverse agonist effects at the h5-HT<sub>7(b)</sub> splice variant.<ref name="pmid11906971"/>
[[receptor antagonist|Neutral antagonists]] (also known as silent antagonists) bind the receptor and have no [[Efficacy|intrinsic activity]] but will block the activity of agonists or inverse agonists. [[Inverse agonists]] inhibit the [[Receptor (biochemistry)#Constitutive activity|constitutive activity]] of the receptor, producing functional effects opposite to those of agonists (at the 5-HT<sub>7</sub> receptor: ↓cAMP).<ref name="pmid17897083">{{cite journal | vauthors = Pittalà V, Salerno L, Modica M, Siracusa MA, Romeo G | title = 5-HT7 receptor ligands: recent developments and potential therapeutic applications | journal = Mini Reviews in Medicinal Chemistry | volume = 7 | issue = 9 | pages = 945–60 | date = September 2007 | pmid = 17897083 | doi = 10.2174/138955707781662663 }}</ref><ref name="pmid15032609">{{cite journal | vauthors = Leopoldo M | title = Serotonin(7) receptors (5-HT(7)Rs) and their ligands | journal = Current Medicinal Chemistry | volume = 11 | issue = 5 | pages = 629–61 | date = March 2004 | pmid = 15032609 | doi = 10.2174/0929867043455828 }}</ref> Neutral antagonists and inverse agonists are typically referred to collectively as "antagonists" and, in the case of the 5-HT<sub>7</sub> receptor, differentiation between neutral antagonists and inverse agonists is problematic due to differing levels inverse agonist efficacy between receptor splice variants. For instance, mesulergine and metergoline are reported to be neutral antagonists at the h5-HT<sub>7(a)</sub> and h5-HT<sub>7(d)</sub> receptor isoforms but these drugs display marked inverse agonist effects at the h5-HT<sub>7(b)</sub> splice variant.<ref name="pmid11906971"/>


{{div col|3}}
{{Div col|colwidth=30em}}
* 3-{4-[4-(4-chlorophenyl)-piperazin-1-yl]-butyl}-3-ethyl-6-fluoro-1,3-dihydro-2''H''-indol-2-one<ref name="pmid18361484">{{cite journal | vauthors = Volk B, Barkóczy J, Hegedus E, Udvari S, Gacsályi I, Mezei T, Pallagi K, Kompagne H, Lévay G, Egyed A, Hársing LG, Spedding M, Simig G | title = (Phenylpiperazinyl-butyl)oxindoles as selective 5-HT7 receptor antagonists | journal = Journal of Medicinal Chemistry | volume = 51 | issue = 8 | pages = 2522–32 | date = April 2008 | pmid = 18361484 | doi = 10.1021/jm070279v }}</ref>
* 3-{4-[4-(4-chlorophenyl)-piperazin-1-yl]-butyl}-3-ethyl-6-fluoro-1,3-dihydro-2''H''-indol-2-one<ref name="pmid18361484">{{cite journal | vauthors = Volk B, Barkóczy J, Hegedus E, Udvari S, Gacsályi I, Mezei T, Pallagi K, Kompagne H, Lévay G, Egyed A, Hársing LG, Spedding M, Simig G | title = (Phenylpiperazinyl-butyl)oxindoles as selective 5-HT7 receptor antagonists | journal = Journal of Medicinal Chemistry | volume = 51 | issue = 8 | pages = 2522–32 | date = April 2008 | pmid = 18361484 | doi = 10.1021/jm070279v }}</ref>
* [[Amisulpride]]<ref name="pmid19337725">{{cite journal | vauthors = Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL | title = Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo | journal = Psychopharmacology | volume = 205 | issue = 1 | pages = 119–28 | date = July 2009 | pmid = 19337725 | pmc = 2821721 | doi = 10.1007/s00213-009-1521-8 }}</ref>
* [[Amisulpride]]<ref name="pmid19337725">{{cite journal | vauthors = Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL | title = Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo | journal = Psychopharmacology | volume = 205 | issue = 1 | pages = 119–28 | date = July 2009 | pmid = 19337725 | pmc = 2821721 | doi = 10.1007/s00213-009-1521-8 }}</ref>
Line 95: Line 94:


Inactivating antagonists are non-competitive antagonists that render the receptor persistently insensitive to agonist, which resembles receptor desensitization. Inactivation of the 5-HT<sub>7</sub> receptor, however, does not arise from the classically described mechanisms of receptor desensitization via receptor phosphorylation, beta-arrestin recruitment, and receptor internalization.<ref name="pmid9606723">{{cite journal | vauthors = Zhang J, Ferguson SS, Barak LS, Aber MJ, Giros B, Lefkowitz RJ, Caron MG | title = Molecular mechanisms of G protein-coupled receptor signaling: role of G protein-coupled receptor kinases and arrestins in receptor desensitization and resensitization | journal = Receptors & Channels | volume = 5 | issue = 3–4 | pages = 193–9 | year = 1997 | pmid = 9606723 }}</ref> Inactivating antagonists all likely interact with the 5-HT<sub>7</sub> receptor in an irreversible/pseudo-irreversible manner, as is the case with [<sup>3</sup>H]risperidone.<ref name="pmid16870886">{{cite journal | vauthors = Smith C, Rahman T, Toohey N, Mazurkiewicz J, Herrick-Davis K, Teitler M | title = Risperidone irreversibly binds to and inactivates the h5-HT7 serotonin receptor | journal = Molecular Pharmacology | volume = 70 | issue = 4 | pages = 1264–70 | date = October 2006 | pmid = 16870886 | doi = 10.1124/mol.106.024612 }}</ref><ref name="pmid18996971">{{cite journal | vauthors = Knight JA, Smith C, Toohey N, Klein MT, Teitler M | title = Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-Hydroxytryptamine7 receptor by risperidone, 9-OH-Risperidone, and other inactivating antagonists | journal = Molecular Pharmacology | volume = 75 | issue = 2 | pages = 374–80 | date = February 2009 | pmid = 18996971 | pmc = 2671286 | doi = 10.1124/mol.108.052084 }}</ref>
Inactivating antagonists are non-competitive antagonists that render the receptor persistently insensitive to agonist, which resembles receptor desensitization. Inactivation of the 5-HT<sub>7</sub> receptor, however, does not arise from the classically described mechanisms of receptor desensitization via receptor phosphorylation, beta-arrestin recruitment, and receptor internalization.<ref name="pmid9606723">{{cite journal | vauthors = Zhang J, Ferguson SS, Barak LS, Aber MJ, Giros B, Lefkowitz RJ, Caron MG | title = Molecular mechanisms of G protein-coupled receptor signaling: role of G protein-coupled receptor kinases and arrestins in receptor desensitization and resensitization | journal = Receptors & Channels | volume = 5 | issue = 3–4 | pages = 193–9 | year = 1997 | pmid = 9606723 }}</ref> Inactivating antagonists all likely interact with the 5-HT<sub>7</sub> receptor in an irreversible/pseudo-irreversible manner, as is the case with [<sup>3</sup>H]risperidone.<ref name="pmid16870886">{{cite journal | vauthors = Smith C, Rahman T, Toohey N, Mazurkiewicz J, Herrick-Davis K, Teitler M | title = Risperidone irreversibly binds to and inactivates the h5-HT7 serotonin receptor | journal = Molecular Pharmacology | volume = 70 | issue = 4 | pages = 1264–70 | date = October 2006 | pmid = 16870886 | doi = 10.1124/mol.106.024612 }}</ref><ref name="pmid18996971">{{cite journal | vauthors = Knight JA, Smith C, Toohey N, Klein MT, Teitler M | title = Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-Hydroxytryptamine7 receptor by risperidone, 9-OH-Risperidone, and other inactivating antagonists | journal = Molecular Pharmacology | volume = 75 | issue = 2 | pages = 374–80 | date = February 2009 | pmid = 18996971 | pmc = 2671286 | doi = 10.1124/mol.108.052084 }}</ref>
{{div col|30em}}
{{Div col|colwidth=30em}}
* [[Bromocriptine]]<ref name="pmid18996971"/>
* [[Bromocriptine]]<ref name="pmid18996971"/>
* [[Lisuride]]<ref name="pmid18996971"/>
* [[Lisuride]]<ref name="pmid18996971"/>
Line 105: Line 104:


== See also ==
== See also ==
{{div col|3}}
{{Div col|colwidth=30em}}
* [[5-HT receptor]]
* [[5-HT receptor]]
* [[5-HT1 receptor|5-HT<sub>1</sub> receptor]]
* [[5-HT1 receptor|5-HT<sub>1</sub> receptor]]
Line 127: Line 126:


{{DEFAULTSORT:5-Ht7 Receptor}}
{{DEFAULTSORT:5-Ht7 Receptor}}
[[Category:Serotonin receptors]]
[[Category:Serotonin receptors]]

Latest revision as of 22:56, 30 December 2018

VALUE_ERROR (nil)
Identifiers
Aliases
External IDsGeneCards: [1]
Orthologs
SpeciesHumanMouse
Entrez

n/a

n/a

Ensembl

n/a

n/a

UniProt

n/a

n/a

RefSeq (mRNA)

n/a

n/a

RefSeq (protein)

n/a

n/a

Location (UCSC)n/an/a
PubMed searchn/an/a
Wikidata
View/Edit Human

The 5-HT7 receptor is a member of the GPCR superfamily of cell surface receptors and is activated by the neurotransmitter serotonin (5-hydroxytryptamine, 5-HT)[1] The 5-HT7 receptor is coupled to Gs (stimulates the production of the intracellular signaling molecule cAMP)[2][3] and is expressed in a variety of human tissues, particularly in the brain, the gastrointestinal tract, and in various blood vessels.[3] This receptor has been a drug development target for the treatment of several clinical disorders.[4] The 5-HT7 receptor is encoded by the HTR7 gene, which in humans is transcribed into 3 different splice variants.[5]

Function

When the 5-HT7 receptor is activated by serotonin, it sets off a cascade of events starting with release of the stimulatory G protein Gs from the GPCR complex. Gs in turn activates adenylate cyclase which increases intracellular levels of the second messenger cAMP.

The 5-HT7 receptor plays a role in smooth muscle relaxation within the vasculature and in the gastrointestinal tract.[1] The highest 5-HT7 receptor densities are in the thalamus and hypothalamus, and it is present at higher densities also in the hippocampus and cortex. The 5-HT7 receptor is involved in thermoregulation, circadian rhythm, learning and memory, and sleep. It is also speculated that this receptor may be involved in mood regulation, suggesting that it may be a useful target in the treatment of depression.[6][7]

Variants

Three splice variants have been identified in humans (designated h5-HT7(a), h5-HT7(b), and h5-HT7(d)), which encode receptors that differ in their carboxy terminals.[5] The h5-HT7(a) is the full length receptor (445 amino acids),[3] while the h5-HT7(b) is truncated at amino acid 432 due to alternative splice donor site. The h5-HT7(d) is a distinct isoform of the receptor: the retention of an exon cassette in the region encoding the carboxyl terminal results a 479-amino acid receptor with a c-terminus markedly different from the h5-HT7(a). A 5-HT7(c) splice variant is detectable in rat tissue but is not expressed in humans. Conversely, rats do not express a splice variant homologous to the h5-HT7(d), as the rat 5-HT7 gene lacks the exon necessary to encode this isoform.[5] Drug binding affinities are similar across the three human splice variants;[8] however, inverse agonist efficacies appear to differ between the splice variants.[9]

Discovery

In 1983, evidence for a 5-HT1-like receptor was first found.[10] Ten years later, 5-HT7 receptor was cloned and characterized.[3] It has since become clear that the receptor described in 1983 is 5-HT7.[11]

Clinical significance

This receptor gene is a candidate locus for involvement in autism and other neuropsychiatric conditions.[12]

Ligands

Numerous orthosteric ligands of moderate to high affinity are known. Signaling biased ligands were discovered and developed in 2018.[13]

Agonists

Agonists mimic the effects of the endogenous ligand, which is serotonin at the 5-HT7 receptor (↑cAMP).

Antagonists

Neutral antagonists (also known as silent antagonists) bind the receptor and have no intrinsic activity but will block the activity of agonists or inverse agonists. Inverse agonists inhibit the constitutive activity of the receptor, producing functional effects opposite to those of agonists (at the 5-HT7 receptor: ↓cAMP).[23][24] Neutral antagonists and inverse agonists are typically referred to collectively as "antagonists" and, in the case of the 5-HT7 receptor, differentiation between neutral antagonists and inverse agonists is problematic due to differing levels inverse agonist efficacy between receptor splice variants. For instance, mesulergine and metergoline are reported to be neutral antagonists at the h5-HT7(a) and h5-HT7(d) receptor isoforms but these drugs display marked inverse agonist effects at the h5-HT7(b) splice variant.[9]

Inactivating antagonists

Inactivating antagonists are non-competitive antagonists that render the receptor persistently insensitive to agonist, which resembles receptor desensitization. Inactivation of the 5-HT7 receptor, however, does not arise from the classically described mechanisms of receptor desensitization via receptor phosphorylation, beta-arrestin recruitment, and receptor internalization.[32] Inactivating antagonists all likely interact with the 5-HT7 receptor in an irreversible/pseudo-irreversible manner, as is the case with [3H]risperidone.[33][34]

See also

References

  1. ↑ 1.0 1.1 Vanhoenacker P, Haegeman G, Leysen JE (February 2000). "5-HT7 receptors: current knowledge and future prospects". Trends in Pharmacological Sciences. 21 (2): 70–7. doi:10.1016/S0165-6147(99)01432-7. PMID 10664612.
  2. ↑ Ruat M, Traiffort E, Leurs R, Tardivel-Lacombe J, Diaz J, Arrang JM, Schwartz JC (September 1993). "Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation". Proceedings of the National Academy of Sciences of the United States of America. 90 (18): 8547–51. doi:10.1073/pnas.90.18.8547. PMC 47394. PMID 8397408.
  3. ↑ 3.0 3.1 3.2 3.3 Bard JA, Zgombick J, Adham N, Vaysse P, Branchek TA, Weinshank RL (November 1993). "Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase". The Journal of Biological Chemistry. 268 (31): 23422–6. PMID 8226867.
  4. ↑ Mnie-Filali O, Lambás-Señas L, Zimmer L, Haddjeri N (December 2007). "5-HT7 receptor antagonists as a new class of antidepressants". Drug News & Perspectives. 20 (10): 613–8. doi:10.1358/dnp.2007.20.10.1181354. PMID 18301795.
  5. ↑ 5.0 5.1 5.2 Heidmann DE, Metcalf MA, Kohen R, Hamblin MW (April 1997). "Four 5-hydroxytryptamine7 (5-HT7) receptor isoforms in human and rat produced by alternative splicing: species differences due to altered intron-exon organization". Journal of Neurochemistry. 68 (4): 1372–81. doi:10.1046/j.1471-4159.1997.68041372.x. PMID 9084407.
  6. ↑ Hedlund PB, Sutcliffe JG (September 2004). "Functional, molecular and pharmacological advances in 5-HT7 receptor research". Trends in Pharmacological Sciences. 25 (9): 481–6. doi:10.1016/j.tips.2004.07.002. PMID 15559250.
  7. ↑ Naumenko VS, Popova NK, Lacivita E, Leopoldo M, Ponimaskin EG (July 2014). "Interplay between serotonin 5-HT1A and 5-HT7 receptors in depressive disorders". CNS Neuroscience & Therapeutics. 20 (7): 582–90. doi:10.1111/cns.12247. PMID 24935787.
  8. ↑ Krobert KA, Bach T, Syversveen T, Kvingedal AM, Levy FO (June 2001). "The cloned human 5-HT7 receptor splice variants: a comparative characterization of their pharmacology, function and distribution". Naunyn-Schmiedeberg's Archives of Pharmacology. 363 (6): 620–32. doi:10.1007/s002100000369. PMID 11414657.
  9. ↑ 9.0 9.1 Krobert KA, Levy FO (March 2002). "The human 5-HT7 serotonin receptor splice variants: constitutive activity and inverse agonist effects". British Journal of Pharmacology. 135 (6): 1563–71. doi:10.1038/sj.bjp.0704588. PMC 1573253. PMID 11906971.
  10. ↑ Feniuk W, Humphrey PP, Watts AD (December 1983). "5-Hydroxytryptamine-induced relaxation of isolated mammalian smooth muscle". European Journal of Pharmacology. 96 (1–2): 71–8. doi:10.1016/0014-2999(83)90530-7. PMID 6662198.
  11. ↑ Hoyer D, Hannon JP, Martin GR (April 2002). "Molecular, pharmacological and functional diversity of 5-HT receptors". Pharmacology Biochemistry and Behavior. 71 (4): 533–54. doi:10.1016/S0091-3057(01)00746-8. PMID 11888546.
  12. ↑ Lassig JP, Vachirasomtoon K, Hartzell K, Leventhal M, Courchesne E, Courchesne R, Lord C, Leventhal BL, Cook EH (October 1999). "Physical mapping of the serotonin 5-HT(7) receptor gene (HTR7) to chromosome 10 and pseudogene (HTR7P) to chromosome 12, and testing of linkage disequilibrium between HTR7 and autistic disorder". American Journal of Medical Genetics. 88 (5): 472–5. doi:10.1002/(SICI)1096-8628(19991015)88:5<472::AID-AJMG7>3.0.CO;2-G. PMID 10490701.
  13. ↑ Kim Y, Kim H, Lee J, Lee JK, Min SJ, Seong J, Rhim H, Tae J, Lee HJ, Choo H (August 2018). "Discovery of β-Arrestin Biased Ligands of 5-HT7R". J. Med. Chem. 61 (16): 7218–7233. doi:10.1021/acs.jmedchem.8b00642. PMID 30028132.
  14. ↑ Sprouse J, Reynolds L, Li X, Braselton J, Schmidt A (January 2004). "8-OH-DPAT as a 5-HT7 agonist: phase shifts of the circadian biological clock through increases in cAMP production". Neuropharmacology. 46 (1): 52–62. doi:10.1016/j.neuropharm.2003.08.007. PMID 14654097.
  15. ↑ Davies MA, Sheffler DJ, Roth BL. Aripiprazole: A Novel Atypical Antipsychotic Drug With a Uniquely Robust Pharmacology. CNS Drug Reviews [Internet]. 2004 [cited 2013 Aug 4];10(4):317–36. Available from: http://onlinelibrary.wiley.com/doi/10.1111/j.1527-3458.2004.tb00030.x/pdf
  16. ↑ Brenchat A, Ejarque M, Zamanillo D, Vela JM, Romero L (August 2011). "Potentiation of morphine analgesia by adjuvant activation of 5-HT7 receptors". Journal of Pharmacological Sciences. 116 (4): 388–91. doi:10.1254/jphs.11039sc. PMID 21778664.
  17. ↑ Brenchat A, Nadal X, Romero L, Ovalle S, Muro A, Sánchez-Arroyos R, Portillo-Salido E, Pujol M, Montero A, Codony X, Burgueño J, Zamanillo D, Hamon M, Maldonado R, Vela JM (June 2010). "Pharmacological activation of 5-HT7 receptors reduces nerve injury-induced mechanical and thermal hypersensitivity". Pain. 149 (3): 483–94. doi:10.1016/j.pain.2010.03.007. PMID 20399562.
  18. ↑ Brenchat A, Romero L, García M, Pujol M, Burgueño J, Torrens A, Hamon M, Baeyens JM, Buschmann H, Zamanillo D, Vela JM (February 2009). "5-HT7 receptor activation inhibits mechanical hypersensitivity secondary to capsaicin sensitization in mice". Pain. 141 (3): 239–47. doi:10.1016/j.pain.2008.11.009. PMID 19118950.
  19. ↑ Powell SL, Gödecke T, Nikolic D, Chen SN, Ahn S, Dietz B, Farnsworth NR, van Breemen RB, Lankin DC, Pauli GF, Bolton JL (December 2008). "In vitro serotonergic activity of black cohosh and identification of N(omega)-methylserotonin as a potential active constituent". Journal of Agricultural and Food Chemistry. 56 (24): 11718–26. doi:10.1021/jf803298z. PMC 3684073. PMID 19049296.
  20. ↑ Leopoldo M, Lacivita E, Contino M, Colabufo NA, Berardi F, Perrone R (August 2007). "Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2". Journal of Medicinal Chemistry. 50 (17): 4214–21. doi:10.1021/jm070487n. PMID 17649988.
  21. ↑ Leopoldo M, Berardi F, Colabufo NA, Contino M, Lacivita E, Niso M, Perrone R, Tortorella V (December 2004). "Structure-affinity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinealkylamides, a new class of 5-hydroxytryptamine7 receptor agents". Journal of Medicinal Chemistry. 47 (26): 6616–24. doi:10.1021/jm049702f. PMID 15588097.
  22. ↑ Hogendorf AS, Hogendorf A, Kurczab R, Satała G, Lenda T, Walczak M, Latacz G, Handzlik J, Kieć-Kononowicz K, Wierońska JM, Woźniak M, Cieślik P, Bugno R, Staroń J, Bojarski AJ (May 2017). "Low-basicity 5-HT7 Receptor Agonists Synthesized Using the van Leusen Multicomponent Protocol". Scientific Reports. 7 (1444): 1444. doi:10.1038/s41598-017-00822-4. PMC 5431432. PMID 28473721.
  23. ↑ Pittalà V, Salerno L, Modica M, Siracusa MA, Romeo G (September 2007). "5-HT7 receptor ligands: recent developments and potential therapeutic applications". Mini Reviews in Medicinal Chemistry. 7 (9): 945–60. doi:10.2174/138955707781662663. PMID 17897083.
  24. ↑ Leopoldo M (March 2004). "Serotonin(7) receptors (5-HT(7)Rs) and their ligands". Current Medicinal Chemistry. 11 (5): 629–61. doi:10.2174/0929867043455828. PMID 15032609.
  25. ↑ Volk B, Barkóczy J, Hegedus E, Udvari S, Gacsályi I, Mezei T, Pallagi K, Kompagne H, Lévay G, Egyed A, Hársing LG, Spedding M, Simig G (April 2008). "(Phenylpiperazinyl-butyl)oxindoles as selective 5-HT7 receptor antagonists". Journal of Medicinal Chemistry. 51 (8): 2522–32. doi:10.1021/jm070279v. PMID 18361484.
  26. ↑ Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL (July 2009). "Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo". Psychopharmacology. 205 (1): 119–28. doi:10.1007/s00213-009-1521-8. PMC 2821721. PMID 19337725.
  27. ↑ 27.0 27.1 Romero G, Pujol M, Pauwels PJ (October 2006). "Reanalysis of constitutively active rat and human 5-HT7(a) receptors in HEK-293F cells demonstrates lack of silent properties for reported neutral antagonists". Naunyn-Schmiedeberg's Archives of Pharmacology. 374 (1): 31–9. doi:10.1007/s00210-006-0093-y. PMID 16967291.
  28. ↑ Forbes IT, Dabbs S, Duckworth DM, Jennings AJ, King FD, Lovell PJ, Brown AM, Collin L, Hagan JJ, Middlemiss DN, Riley GJ, Thomas DR, Upton N (February 1998). "(R)-3,N-dimethyl-N-[1-methyl-3-(4-methyl-piperidin-1-yl) propyl]benzenesulfonamide: the first selective 5-HT7 receptor antagonist". Journal of Medicinal Chemistry. 41 (5): 655–7. doi:10.1021/jm970519e. PMID 9513592.
  29. ↑ 29.0 29.1 Mahé C, Loetscher E, Feuerbach D, Müller W, Seiler MP, Schoeffter P (July 2004). "Differential inverse agonist efficacies of SB-258719, SB-258741 and SB-269970 at human recombinant serotonin 5-HT7 receptors". European Journal of Pharmacology. 495 (2–3): 97–102. doi:10.1016/j.ejphar.2004.05.033. PMID 15249157.
  30. ↑ Lovell PJ, Bromidge SM, Dabbs S, Duckworth DM, Forbes IT, Jennings AJ, King FD, Middlemiss DN, Rahman SK, Saunders DV, Collin LL, Hagan JJ, Riley GJ, Thomas DR (February 2000). "A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970)". Journal of Medicinal Chemistry. 43 (3): 342–5. doi:10.1021/jm991151j. PMID 10669560.
  31. ↑ Forbes IT, Douglas S, Gribble AD, Ife RJ, Lightfoot AP, Garner AE, Riley GJ, Jeffrey P, Stevens AJ, Stean TO, Thomas DR (November 2002). "SB-656104-A: a novel 5-HT(7) receptor antagonist with improved in vivo properties". Bioorganic & Medicinal Chemistry Letters. 12 (22): 3341–4. doi:10.1016/S0960-894X(02)00690-X. PMID 12392747.
  32. ↑ Zhang J, Ferguson SS, Barak LS, Aber MJ, Giros B, Lefkowitz RJ, Caron MG (1997). "Molecular mechanisms of G protein-coupled receptor signaling: role of G protein-coupled receptor kinases and arrestins in receptor desensitization and resensitization". Receptors & Channels. 5 (3–4): 193–9. PMID 9606723.
  33. ↑ 33.0 33.1 33.2 33.3 Smith C, Rahman T, Toohey N, Mazurkiewicz J, Herrick-Davis K, Teitler M (October 2006). "Risperidone irreversibly binds to and inactivates the h5-HT7 serotonin receptor". Molecular Pharmacology. 70 (4): 1264–70. doi:10.1124/mol.106.024612. PMID 16870886.
  34. ↑ 34.0 34.1 34.2 34.3 Knight JA, Smith C, Toohey N, Klein MT, Teitler M (February 2009). "Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-Hydroxytryptamine7 receptor by risperidone, 9-OH-Risperidone, and other inactivating antagonists". Molecular Pharmacology. 75 (2): 374–80. doi:10.1124/mol.108.052084. PMC 2671286. PMID 18996971.

External links

  • "5-HT7". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology.
  • Human HTR7 genome location and HTR7 gene details page in the UCSC Genome Browser.

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

Retrieved from "https://www.wikidoc.org/index.php?title=5-HT7_receptor&oldid=1527314"